IL101348A0 - Polyethylene glycol protein conjugates,their preparation and pharmaceutical compositions containing them - Google Patents

Polyethylene glycol protein conjugates,their preparation and pharmaceutical compositions containing them

Info

Publication number
IL101348A0
IL101348A0 IL101348A IL10134892A IL101348A0 IL 101348 A0 IL101348 A0 IL 101348A0 IL 101348 A IL101348 A IL 101348A IL 10134892 A IL10134892 A IL 10134892A IL 101348 A0 IL101348 A0 IL 101348A0
Authority
IL
Israel
Prior art keywords
polyethylene glycol
preparation
protein conjugates
pharmaceutical compositions
compositions containing
Prior art date
Application number
IL101348A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27101069&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL101348(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL101348A0 publication Critical patent/IL101348A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/964—Chemistry: molecular biology and microbiology including enzyme-ligand conjugate production, e.g. reducing rate of nonproductive linkage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815—Carrier is a synthetic polymer
    • Y10S530/816—Attached to the carrier via a bridging agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Vending Machines For Individual Products (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL101348A 1991-03-25 1992-03-24 Polyethylene glycol protein conjugates,their preparation and pharmaceutical compositions containing them IL101348A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67400191A 1991-03-25 1991-03-25
US07/767,000 US5595732A (en) 1991-03-25 1991-09-27 Polyethylene-protein conjugates

Publications (1)

Publication Number Publication Date
IL101348A0 true IL101348A0 (en) 1992-11-15

Family

ID=27101069

Family Applications (1)

Application Number Title Priority Date Filing Date
IL101348A IL101348A0 (en) 1991-03-25 1992-03-24 Polyethylene glycol protein conjugates,their preparation and pharmaceutical compositions containing them

Country Status (32)

Country Link
US (7) US5595732A (cs)
EP (1) EP0510356B1 (cs)
JP (1) JP2637010B2 (cs)
KR (1) KR920018079A (cs)
CN (2) CN1038035C (cs)
AT (1) ATE176159T1 (cs)
AU (2) AU657311B2 (cs)
BG (1) BG60800B2 (cs)
BR (1) BR9201015A (cs)
CA (1) CA2063886C (cs)
CS (1) CS87192A3 (cs)
CY (1) CY2169B1 (cs)
DE (1) DE69228269T2 (cs)
DK (1) DK0510356T3 (cs)
EE (1) EE9400356A (cs)
ES (1) ES2128329T3 (cs)
FI (2) FI107927B (cs)
GR (1) GR3030049T3 (cs)
HU (2) HUT60512A (cs)
IE (1) IE920936A1 (cs)
IL (1) IL101348A0 (cs)
IS (1) IS3824A (cs)
MW (1) MW1892A1 (cs)
MX (1) MX9201298A (cs)
MY (1) MY131095A (cs)
NO (1) NO921142L (cs)
NZ (2) NZ242084A (cs)
OA (1) OA09760A (cs)
RO (1) RO109543B1 (cs)
SI (1) SI9210294A (cs)
ZA (1) ZA922110B (cs)
ZW (1) ZW4392A1 (cs)

Families Citing this family (254)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
AU5006993A (en) * 1992-08-21 1994-03-15 Enzon, Inc. Novel attachment of polyalkylene oxides to bio-effecting substances
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5478860A (en) * 1993-06-04 1995-12-26 Inex Pharmaceuticals Corp. Stable microemulsions for hydrophobic compound delivery
KR100361933B1 (ko) 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
US5965566A (en) * 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5622986A (en) * 1993-10-20 1997-04-22 Enzon, Inc. 2'-and/or 7-substituted taxanes
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
WO1995013090A1 (en) * 1993-11-10 1995-05-18 Enzon, Inc. Improved interferon polymer conjugates
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US7008624B1 (en) * 1995-02-22 2006-03-07 Immunex Corporation Antagonists of interleukin-15
DE19512484A1 (de) * 1995-04-04 1996-10-17 Bayer Ag Kohlenhydratmodifizierte Cytostatika
DE19514087A1 (de) * 1995-04-13 1996-10-17 Deutsches Krebsforsch Konjugat aus einem Wirkstoff, einem Polyether und ggfs. einem nicht als körperfremd angesehenen, nativen Protein
ES2093593T1 (es) * 1995-05-05 1997-01-01 Hoffmann La Roche Proteinas obesas (ob) recombinantes.
ZA963530B (en) * 1995-05-05 1996-11-05 Hoffmann La Roche Recombinant obese (ob) proteins
CA2236591C (en) 1995-11-02 2012-01-03 Schering Corporation Continuous low-dose cytokine infusion therapy
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6025324A (en) * 1996-05-15 2000-02-15 Hoffmann-La Roche Inc. Pegylated obese (ob) protein compositions
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
DE69800640T2 (de) * 1997-01-29 2001-07-05 Polymasc Pharmaceuticals Plc, London Pegylationsverfahren
WO1998035551A1 (en) 1997-02-13 1998-08-20 Lxr Biotechnology Inc. Organ preservation solution
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
DK0968291T3 (da) 1997-02-21 2004-06-07 Genentech Inc Antistoffragment-polymerkonjugater
US5985263A (en) * 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US5981709A (en) * 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US6468532B1 (en) 1998-01-22 2002-10-22 Genentech, Inc. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
US6458355B1 (en) 1998-01-22 2002-10-01 Genentech, Inc. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
US7005504B2 (en) * 1998-01-22 2006-02-28 Genentech, Inc. Antibody fragment-peg conjugates
FR2774687B1 (fr) * 1998-02-06 2002-03-22 Inst Nat Sante Rech Med Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
US6180096B1 (en) * 1998-03-26 2001-01-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
SI1075281T1 (en) * 1998-04-28 2005-02-28 Applied Research Systems Ars Holding N.V. Polyol-ifn-beta conjugates
TWI277424B (en) 1998-05-15 2007-04-01 Schering Corp Combination therapy for eradicating detectable NCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
IL139786A0 (en) * 1998-06-08 2002-02-10 Hoffmann La Roche Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
LT2599503T (lt) 1998-10-16 2017-06-26 Biogen Ma Inc. Interferono beta-1a polimero konjugatai ir jų panaudojimas
WO2000023472A2 (en) 1998-10-16 2000-04-27 Biogen, Inc. Interferon-beta fusion proteins and uses
PT2319928E (pt) * 1998-10-23 2013-06-28 Kirin Amgen Inc Péptidos diméricos de trombopoietina que simulam a ligação ao receptor mpl e têm actividade trombopoiética
US6923966B2 (en) 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
CO5170404A1 (es) 1999-04-08 2002-06-27 Schering Corp Terapia para melanomas
US6362162B1 (en) 1999-04-08 2002-03-26 Schering Corporation CML Therapy
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
JO2291B1 (en) 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
WO2001005819A1 (en) * 1999-07-15 2001-01-25 Kuhnil Pharm. Co., Ltd. Novel water soluble-cyclosporine conjugated compounds
BR0015506A (pt) 1999-11-12 2002-07-23 Maxygen Holdings Ltd Conjugados de interferon gama, métodos para sua preparação, composições farmacêuticas que compreendem ás moléculas e seu uso no tratamento de doenças
CN1309423C (zh) 1999-11-12 2007-04-11 马克西根控股公司 干扰素γ偶联物
ES2327606T3 (es) 2000-01-10 2009-11-02 Maxygen Holdings Ltd Conjugados de g-csf.
WO2001058935A2 (en) 2000-02-11 2001-08-16 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
US7109303B2 (en) * 2000-02-15 2006-09-19 Fondazione Centro San Raffaele Del Monte Tabor Modified cytokines for use in cancer therapy
IT1317835B1 (it) * 2000-02-15 2003-07-15 San Raffaele Centro Fond Citochine modificate per uso nella terapia del cancro.
US7309694B2 (en) * 2000-02-15 2007-12-18 Fondazione Centro San Raffaele Del Monte Tabor Modified cytokines for use in cancer therapy
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
EP1292337A2 (en) 2000-06-08 2003-03-19 La Jolla Pharmaceutical Multivalent platform molecules comprising high molecular weight polyethylene oxide
US7208167B2 (en) * 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
US7118737B2 (en) 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
WO2002019963A2 (en) * 2000-09-08 2002-03-14 Gryphon Therapeutics, Inc. Synthetic erythropoiesis stimulating proteins
US20020065397A1 (en) * 2000-10-12 2002-05-30 Joseph Roberts Protecting therapeutic compositions from host-mediated inactivation
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
YU48703A (sh) 2001-02-27 2006-05-25 Maxygen Aps Novi interferonu beta-slični molekuli
US6958388B2 (en) 2001-04-06 2005-10-25 Maxygen, Aps Interferon gamma polypeptide variants
US7038015B2 (en) * 2001-04-06 2006-05-02 Maxygen Holdings, Ltd. Interferon gamma polypeptide variants
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7125558B2 (en) 2001-08-22 2006-10-24 Bioartificial Gel Technologies Inc, Process for the preparation of activated polyethylene glycols
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US6913903B2 (en) 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7166571B2 (en) 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7312192B2 (en) 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7196059B2 (en) 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
UA78726C2 (en) * 2001-11-01 2007-04-25 Sciclone Pharmaceuticals Inc Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment
US20040058865A1 (en) * 2001-11-26 2004-03-25 Danishefsky Samuel J Homing peptide multimers, their preparation and uses
US6956135B2 (en) * 2001-12-11 2005-10-18 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US7041855B2 (en) * 2001-12-11 2006-05-09 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US6916962B2 (en) * 2001-12-11 2005-07-12 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
KR100488351B1 (ko) * 2001-12-11 2005-05-11 선바이오(주) 신규한 폴리에틸렌글리콜-프로피온알데히드 유도체
KR100888371B1 (ko) 2002-01-17 2009-03-13 동아제약주식회사 가지 달린 고분자 유도체와 인터페론 결합체를 포함하는 항바이러스제
GEP20074024B (en) 2002-01-18 2007-01-10 Biogen Idec Inc Polyalkylene glycol comprising a radical for conjugation of biologically active compound
US20030191056A1 (en) * 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
GB0209896D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate
GB0209893D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
WO2003105768A2 (en) 2002-06-13 2003-12-24 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
US20040002451A1 (en) * 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
DK1517710T3 (da) 2002-06-21 2011-07-18 Novo Nordisk Healthcare Ag Pegylerede faktor VII-glycoformer
CN104193791A (zh) 2002-06-28 2014-12-10 埃迪尼克斯医药公司 用于治疗黄病毒感染的修饰的2’和3’-核苷前药
WO2004005341A2 (en) * 2002-07-03 2004-01-15 Maxygen Holdings Ltd. Full-length interferon gamma polypeptide variants
EP1382352A1 (de) * 2002-07-19 2004-01-21 GBF Gesellschaft für Biotechnologische Forschung mbH Bisacyloxypropylcystein-Konjugate und deren Verwendung
KR101101261B1 (ko) 2002-07-19 2012-01-04 인스티튜트 오브 머티어리얼스 리서치 & 엔지니어링 생체분해성 삼블럭 공중합체, 이의 합성 방법, 및이로부터 제조된 하이드로겔 및 생체물질
JP4451308B2 (ja) * 2002-07-24 2010-04-14 エフ．ホフマン−ラ ロシュ アーゲー ポリアルキレングリコール酸添加剤
US7563507B2 (en) * 2002-08-16 2009-07-21 University Of Massachusetts Pyridine and related ligand compounds, functionalized nanoparticulate composites and methods of preparation
US7314613B2 (en) * 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
US7217845B2 (en) * 2002-11-25 2007-05-15 Sun Bio, Inc. Bifunctional polyethylene glycol derivatives
EP1628618A4 (en) * 2002-12-26 2009-09-09 Mountain View Pharmaceuticals POLYMER CONJUGATES OF CYTOKINES, CHEMOKINS, GROWTH FACTORS, POLYPEPTIDE HORMONES AND ANTAGONISTS THEREOF WITH PRESERVED RECEPTOR BINDING ACTIVITY
WO2004060299A2 (en) * 2002-12-26 2004-07-22 Mountain View Pharmaceuticals, Inc. Polymer conjugates of interferon-beta with enhanced biological potency
US20040176655A1 (en) * 2003-02-05 2004-09-09 Ayoub Paul Marie Methods of preparing branched alkyl aromatic hydrocarbons
US20050079155A1 (en) * 2003-03-20 2005-04-14 Xencor, Inc. Generating protein pro-drugs using reversible PPG linkages
CA2458085A1 (en) 2003-03-21 2004-09-21 F. Hoffmann-La Roche Ag Transcriptional activity assay
PT3521297T (pt) 2003-05-30 2022-03-18 Gilead Pharmasset Llc Análogos de nucleosídeo fluorados modificados
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
JP4890253B2 (ja) * 2003-10-09 2012-03-07 アンブレツクス・インコーポレイテツド アジドまたはアセチレン末端水溶性ポリマー
EP1673387B1 (en) 2003-10-10 2010-09-15 Novo Nordisk A/S Il-21 derivatives
EP2633866A3 (en) 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
AU2005211385B2 (en) 2004-02-02 2008-12-11 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
CN1942589A (zh) * 2004-02-02 2007-04-04 Ambrx公司 经修饰的人类生长激素多肽与其用途
US7351787B2 (en) * 2004-03-05 2008-04-01 Bioartificial Gel Technologies, Inc. Process for the preparation of activated polyethylene glycols
AU2005245918A1 (en) * 2004-05-19 2005-12-01 F. Hoffmann-La Roche Ag Interferon-alpha polypeptides and conjugates
US20060194726A1 (en) * 2004-05-25 2006-08-31 Rueger David C Methods of treating cartilage defects
WO2005123113A2 (en) * 2004-06-14 2005-12-29 Intermune, Inc. Interferon compositions and methods of use thereof
BRPI0512235A (pt) 2004-06-18 2008-02-19 Ambrx Inc polipeptìdeos ligadores de antìgenos e seus usos
WO2006005058A2 (en) * 2004-06-30 2006-01-12 Nektar Therapeutics Al, Corporation Polymer-factor ix moiety conjugates
JP2008505928A (ja) * 2004-07-08 2008-02-28 アムジェン　インコーポレーテッド 治療用ペプチド
PL2626368T3 (pl) 2004-07-19 2017-06-30 Biocon Limited Koniugaty insulina-oligomer, ich formulacje i zastosowania
CN101023094B (zh) * 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
MX2007000728A (es) * 2004-07-21 2007-03-15 Ambrx Inc Polipeptidos biosinteticos que utilizan amino acidos no naturalmente codificados.
BRPI0513332A (pt) * 2004-08-12 2008-05-06 Schering Corp formulação de interferon peguilado estável
EP1809301B1 (en) 2004-09-14 2019-11-06 Gilead Pharmasset LLC 2-fluoro-2-alkyl-substituted d-ribonolactone intermediates
MX2007007591A (es) 2004-12-22 2007-07-25 Ambrx Inc Metodos para expresion y purificacion de hormona de crecimiento humano recombinante.
SG161209A1 (en) * 2004-12-22 2010-05-27 Ambrx Inc Formulations of human growth hormone comprising a non-naturally encoded amino acid
AU2005319518B2 (en) * 2004-12-22 2010-09-09 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
KR20070090023A (ko) 2004-12-22 2007-09-04 암브룩스, 인코포레이티드 변형 인간 성장 호르몬
MX2007007877A (es) * 2004-12-27 2007-08-21 Baxter Int Conjugados de polimero-factor de von willebrand.
KR20070099013A (ko) 2005-01-31 2007-10-08 주식회사 에펙타 세포연구소 면역 증강제
US7619067B2 (en) 2005-05-18 2009-11-17 Maxygen, Inc. Evolved interferon-alpha polypeptides
US20070015701A1 (en) * 2005-06-01 2007-01-18 Samuel Zalipsky Macromolecular conjugates of bone morphogenetic protein-7
CA2609205A1 (en) * 2005-06-03 2006-12-14 Ambrx, Inc. Improved human interferon molecules and their uses
WO2006134173A2 (en) 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
AR054778A1 (es) 2005-06-17 2007-07-18 Novartis Ag Uso de sangliferina en hcv
EP1896072A4 (en) * 2005-06-24 2013-01-09 Univ Duke SYSTEM FOR DIRECT HEALTH MANAGEMENT BASED ON HEAT-CONTROLLED BIOPOLYMERS
EP1937824B1 (en) 2005-08-18 2013-03-13 Ambrx, Inc. COMPOSITIONS OF tRNA AND USES THEREOF
US20070123646A1 (en) * 2005-09-13 2007-05-31 Lele Bhalchandra S Protein-polymer conjugates and synthesis thereof
EP1776963A1 (en) * 2005-10-19 2007-04-25 Gbf-Gesellschaft Für Biotechnologische Forschung Mbh Hexosylceramides as adjuvants and their uses in pharmaceutical compositions
SI1954710T1 (sl) * 2005-11-08 2011-08-31 Ambrx Inc Pospeĺ evala za modifikacijo nenaravnih aminokislin in nenaravnih peptidov aminokislin
US20090018029A1 (en) 2005-11-16 2009-01-15 Ambrx, Inc. Methods and Compositions Comprising Non-Natural Amino Acids
SG10201405661QA (en) * 2005-12-14 2014-10-30 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
EP1971355B1 (en) 2005-12-20 2020-03-11 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
AU2007205545B9 (en) 2006-01-12 2012-10-18 Hokusan Co. Ltd. Oral composition containing interferon-alpha
TW200738752A (en) 2006-01-31 2007-10-16 Bayer Schering Pharma Ag Modulation of MDL-1 activity for treatment of inflammatory disease
DE602007008627D1 (de) * 2006-02-14 2010-10-07 Genetix Ltd Zellkulturmedium
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
AU2007245190B2 (en) * 2006-03-31 2011-07-21 Takeda Pharmaceutical Company Limited Pegylated factor VIII
US7825152B2 (en) 2006-04-11 2010-11-02 Novartis Ag Organic compounds and their uses
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
MX2008014685A (es) 2006-05-24 2008-11-27 Novo Nordisk Healthcare Ag Analogos de factor ix con semivida prolongada in vivo.
EP1897557A1 (en) * 2006-09-07 2008-03-12 Helmholtz-Zentrum für Infektionsforschung GmbH Use of glycolipids as adjuvants
US9133495B2 (en) * 2006-09-08 2015-09-15 Ambrx, Inc. Hybrid suppressor tRNA for vertebrate cells
CA2663083A1 (en) * 2006-09-08 2008-03-13 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
MX2009002526A (es) * 2006-09-08 2009-04-16 Ambrx Inc Transcripcion de tarn supresor en celulas de vertebrados.
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
ES2385114T3 (es) 2007-03-30 2012-07-18 Ambrx, Inc. Polipéptidos de FGF-21 modificados y sus usos
CA2685596A1 (en) 2007-05-02 2008-11-13 Ambrx, Inc. Modified interferon beta polypeptides and their uses
ES2664822T3 (es) 2007-10-16 2018-04-23 Biocon Limited Una composición farmacéutica sólida administrable por vía oral y un proceso de la misma
ES2632504T3 (es) 2007-11-20 2017-09-13 Ambrx, Inc. Polipéptidos de insulina modificados y sus usos
US9938333B2 (en) 2008-02-08 2018-04-10 Ambrx, Inc. Modified leptin polypeptides and their uses
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
TWI541020B (zh) 2008-04-17 2016-07-11 巴克斯歐塔公司 生物活性胜肽
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EP2926825A1 (en) 2008-06-27 2015-10-07 Duke University Therapeutic agents comprising elastin-like peptides
EP2318029B1 (en) 2008-07-23 2017-11-01 Ambrx, Inc. Modified bovine g-csf polypeptides and their uses
CN101671390B (zh) * 2008-09-10 2012-10-03 海南四环心脑血管药物研究院有限公司 人干扰素α衍生物及其聚乙二醇化修饰物的制备和用途
MX357314B (es) 2008-09-26 2018-07-04 Ambrx Inc Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales.
NZ592250A (en) 2008-09-26 2012-11-30 Lilly Co Eli Modified animal erythropoietin polypeptides and their uses
NZ617066A (en) 2008-12-23 2015-02-27 Gilead Pharmasset Llc Nucleoside analogs
PA8855601A1 (es) 2008-12-23 2010-07-27 Forformidatos de nucleósidos
WO2010075554A1 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Synthesis of purine nucleosides
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
CN101870728A (zh) 2009-04-23 2010-10-27 派格生物医药(苏州)有限公司 新型Exendin变体及其缀合物
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
US9220746B2 (en) * 2009-06-04 2015-12-29 The University Of North Carolina At Chapel Hill Compounds and methods for treating bone disorders and controlling weight
WO2011009047A2 (en) * 2009-07-16 2011-01-20 Ta Tung Yuan Il-1ra-polymer conjugates
WO2011014882A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. CONTINUOUS SUBCUTANEOUS ADMINISTRATION OF INTERFERON-α TO HEPATITIS C INFECTED PATIENTS
CA2804755C (en) * 2009-08-14 2018-06-05 Phasebio Pharmaceuticals, Inc. Modified vasoactive intestinal peptides
US8475652B2 (en) 2009-10-19 2013-07-02 Jan A. K. Paul Method for purification of uncatalyzed natural fuels from metal ions by means of at least one hemeprotein and use of the at least on hemeprotein
KR20120106942A (ko) 2009-10-30 2012-09-27 베링거 인겔하임 인터내셔날 게엠베하 Ｂｉ２０１３３５, 인터페론 알파 및 리바비린을 포함하는 ｈｃｖ 병용 치료요법을 위한 투여 용법
US20120283171A1 (en) 2009-12-21 2012-11-08 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
US20120283172A1 (en) 2009-12-21 2012-11-08 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
WO2011107591A1 (en) 2010-03-05 2011-09-09 Rigshospitalet Chimeric inhibitor molecules of complement activation
CL2011000718A1 (es) 2010-03-31 2012-04-09 Gilead Pharmasset Llc Proceso para la preparacion de compuestos fosforados enantiomericos.
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
EP2569331A1 (en) 2010-05-10 2013-03-20 Perseid Therapeutics LLC Polypeptide inhibitors of vla4
WO2011161644A1 (en) 2010-06-24 2011-12-29 Panmed Ltd. Treatment of hepatitis c virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
HUE045845T2 (hu) 2010-08-17 2021-12-28 Ambrx Inc Módosított relaxin polipeptidek és felhasználásuk
JP5955322B2 (ja) 2010-09-03 2016-07-20 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 抗ｃ−ｍｅｔ抗体及びその使用方法
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
CN103179974A (zh) 2010-10-05 2013-06-26 诺华有限公司 丙型肝炎病毒感染的新疗法
EP2624826B1 (en) 2010-10-08 2018-07-18 Novartis AG Vitamin e formulations of sulfamide ns3 inhibitors
CA3144697A1 (en) 2010-11-12 2012-05-18 Nektar Therapeutics Conjugates of an il-2 moiety and a polymer
AU2011334984A1 (en) 2010-11-30 2013-07-04 Novartis Ag New treatments of Hepatitis C virus infection
WO2012075140A1 (en) 2010-11-30 2012-06-07 Pharmasset, Inc. Compounds
US8440309B2 (en) 2011-01-31 2013-05-14 Confluent Surgical, Inc. Crosslinked polymers with the crosslinker as therapeutic for sustained release
EP2691094A1 (en) 2011-03-31 2014-02-05 Novartis AG Alisporivir to treat hepatitis c virus infection
BR112013024809A2 (pt) 2011-04-01 2016-09-06 Novartis Ag tratamento para infecção com vírus de hepatite b sozinho ou em combinação com vírus de hepatite delta e doenças do fígado associadas
MA35029B1 (fr) 2011-04-13 2014-04-03 Novartis Ag Traitement de l'infection par le virus de l'hépatite c avec l'alisporivir
EP2717902B1 (en) 2011-06-06 2018-01-24 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
US9486507B2 (en) 2011-06-10 2016-11-08 Biogen Ma Inc. Pro-coagulant compounds and methods of use thereof
KR20140054009A (ko) 2011-07-01 2014-05-08 바이엘 인텔렉쳐 프로퍼티 게엠베하 릴랙신 융합 폴리펩타이드 및 그의 용도
RU2014116988A (ru) 2011-09-27 2015-11-10 Новартис Аг Алиспоривир для лечения инфекции, вызванной вирусом гепатита с
US8767214B2 (en) 2011-10-06 2014-07-01 Nordson Corporation Powder flow detection
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
JP2015509980A (ja) 2012-03-14 2015-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｈｃｖ−ｈｉｖ同時感染患者集団のｈｃｖ感染症を治療するための併用療法
JP2015512900A (ja) 2012-03-28 2015-04-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 特別な患者の遺伝子亜型分集団のｈｃｖ感染症を治療するための併用療法
EP2853273A4 (en) * 2012-04-25 2016-01-13 Daiichi Sankyo Co Ltd PROMOTER FOR BONE REPAIR
KR102172897B1 (ko) 2012-06-08 2020-11-02 서트로 바이오파마, 인크. 부위-특이적 비-천연 아미노산 잔기를 포함하는 항체, 그의 제조 방법 및 그의 사용 방법
EP3135690A1 (en) 2012-06-26 2017-03-01 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
RU2015105588A (ru) 2012-07-19 2016-09-10 Редвуд Байосайнс, Инк. Антитело, специфическое к cd22, и способы его применения
HUE048780T2 (hu) 2012-08-16 2020-09-28 Ipierian Inc Tauopátia kezelésére szolgáló módszerek
DK3584255T3 (da) 2012-08-31 2022-04-04 Sutro Biopharma Inc Modificerede aminosyrer omfattende en azidogruppe
EP2912065A4 (en) 2012-10-25 2016-10-19 True North Therapeutics Inc ANTI COMPLEMENT C1S ANTIBODIES AND USES THEREOF
CA2889197A1 (en) 2012-11-02 2014-05-08 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
EP2922870B1 (en) 2012-11-21 2019-08-07 The Governors of the University of Alberta Immunomodulatory peptides and methods of use thereof
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
SMT202000401T1 (it) 2013-06-10 2020-11-10 Ipierian Inc Metodi di trattamento di una taupatia
EP3019522B1 (en) 2013-07-10 2017-12-13 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
SG11201600919UA (en) 2013-08-27 2016-03-30 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
EP3055298B1 (en) 2013-10-11 2020-04-29 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
BR112016010454A2 (pt) 2013-11-27 2017-12-05 Ipierian Inc métodos para tratar uma taupatia
AU2015255752B2 (en) 2014-05-08 2020-07-23 Immunoforge Co., Ltd. Methods and compositions for treating Cystic Fibrosis
HRP20201725T1 (hr) 2014-08-19 2021-03-05 Biogen Ma Inc. Postupak pegilacije
PE20170950A1 (es) 2014-10-24 2017-07-13 Bristol Myers Squibb Co Polipeptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos
AU2016219513B2 (en) 2015-02-09 2021-09-30 Immunoforge Co., Ltd. Methods and compositions for treating muscle disease and disorders
CN117510633A (zh) 2015-09-02 2024-02-06 伊缪泰普有限公司 抗lag-3抗体
JP7407511B2 (ja) 2015-10-08 2024-01-04 ネクター セラピューティクス ＩＬ－２Ｒβ選択的作動薬と長時間作用型ＩＬ－１５作動薬との併用
MX377531B (es) 2015-11-03 2025-03-10 Hoffmann La Roche Terapia de combinación de un inhibidor del ensamble de la cápside del hbv y un interferón.
EA201892225A1 (ru) 2016-04-04 2019-09-30 БИОВЕРАТИВ ЮЭсЭй ИНК. АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
WO2018087345A1 (en) 2016-11-14 2018-05-17 F. Hoffmann-La Roche Ag COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON
CA3052639A1 (en) 2017-02-08 2018-08-16 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
CN111051512A (zh) 2017-07-11 2020-04-21 辛索克斯公司 非天然核苷酸的掺入及其方法
CN111183149A (zh) 2017-08-03 2020-05-19 辛索克斯公司 用于治疗自身免疫疾病的细胞因子缀合物
EP3849614B1 (en) 2018-09-11 2023-12-20 Ambrx, Inc. Interleukin-2 polypeptide conjugates and their uses
US20220009986A1 (en) 2018-10-19 2022-01-13 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
WO2020163532A1 (en) 2019-02-06 2020-08-13 Synthorx, Inc. Il-2 conjugates and methods of use thereof
CN119455004A (zh) 2019-02-12 2025-02-18 Ambrx公司 包含抗体-tlr激动剂缀合物的组合物、方法和用途
EP4117732A1 (en) 2020-03-11 2023-01-18 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
TW202227449A (zh) 2020-08-20 2022-07-16 美商Ａｍｂｒｘ 公司 抗體－ｔｌｒ促效劑偶聯物、其方法及用途
AU2022249223A1 (en) 2021-04-03 2023-10-12 Ambrx, Inc. Anti-her2 antibody-drug conjugates and uses thereof
CN119431229A (zh) * 2023-08-04 2025-02-14 华为技术有限公司 缩合剂及其在制备异硫氰酸酯中的用途

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE337223B (cs) * 1967-05-23 1971-08-02 Pharmacia Ab
US3619371A (en) * 1967-07-03 1971-11-09 Nat Res Dev Production of a polymeric matrix having a biologically active substance bound thereto
SE343210B (cs) * 1967-12-20 1972-03-06 Pharmacia Ab
DK132327A (cs) * 1968-07-16
BE758425A (fr) * 1969-12-02 1971-04-16 Baxter Laboratories Inc Streptokinase liee chimiquement a une matrice en carbohydrate (
DE2247163A1 (de) * 1972-09-26 1974-03-28 Merck Patent Gmbh Traegermatrix zur fixierung biologisch wirksamer stoffe und verfahren zu ihrer herstellung
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4100271A (en) * 1976-02-26 1978-07-11 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
GB1578348A (en) * 1976-08-17 1980-11-05 Pharmacia Ab Products and a method for the therapeutic suppression of reaginic antibodies responsible for common allergic
US4094744A (en) * 1976-11-18 1978-06-13 W. R. Grace & Co. Water-dispersible protein/polyurethane reaction product
DE2862449D1 (en) * 1977-08-22 1984-11-22 Nat Res Dev Macromolecular covalent conjugates, methods for preparing and pharmaceutical compositions containing them
JPS55110105A (en) * 1979-02-19 1980-08-25 Japan Atom Energy Res Inst Preparation of polymer composition containing physiologically active material
JPS6023084B2 (ja) * 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
JPS5896785A (ja) * 1981-12-04 1983-06-08 Stanley Electric Co Ltd 発光ダイオ−ドの合成樹脂レンズ成形方法
EP0098110B1 (en) * 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4486344A (en) * 1983-03-28 1984-12-04 Miles Laboratories, Inc. Urea-linked immunogens, antibodies, and preparative method
JPS6098988A (ja) * 1983-11-01 1985-06-01 Chemo Sero Therapeut Res Inst Ｌｐｆ−ｈａの精製法
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0154316B1 (en) * 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
GB8430252D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US4732863A (en) * 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
WO1987000056A1 (en) * 1985-06-26 1987-01-15 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) * 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4847079A (en) * 1985-07-29 1989-07-11 Schering Corporation Biologically stable interferon compositions comprising thimerosal
US4818769A (en) * 1985-09-20 1989-04-04 Cetus Corporation Method of controlling stress-related disease in livestock by administration of human IL-2
US5102872A (en) * 1985-09-20 1992-04-07 Cetus Corporation Controlled-release formulations of interleukin-2
US5100664A (en) * 1985-09-20 1992-03-31 Cetus Corporation Human IL-2 as a vaccine adjuvant
US5034514A (en) * 1986-03-17 1991-07-23 Cetus Corporation Novel cross-linking agents
US4797491A (en) * 1986-03-17 1989-01-10 Cetus Corporation Compound 1-(3-(2-pyridyldithio)propionamido)-12-(5-hydrazidoglutaramido)-4,9-dioxadodecane
JPH0443882Y2 (cs) * 1986-06-23 1992-10-16
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4810638A (en) * 1986-07-24 1989-03-07 Miles Inc. Enzyme-labeled antibody reagent with polyalkyleneglycol linking group
US4894226A (en) * 1986-11-14 1990-01-16 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
US4851220A (en) * 1986-11-26 1989-07-25 Schering Corporation Stable oleaginous gel
US4871538A (en) * 1987-07-13 1989-10-03 Schering Corporation Insoluble copper-alpha interferon complex
CA1308377C (en) * 1987-08-21 1992-10-06 Henry Berger, Jr. Complex of polyethyleneglycol and tissue plasminogen activator
US5153265A (en) * 1988-01-20 1992-10-06 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5214131A (en) * 1988-05-06 1993-05-25 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, modified peptides and production thereof
GB8824591D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
AU4660789A (en) * 1988-11-23 1990-06-12 Genentech Inc. Polypeptide derivatives
US4902502A (en) * 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5089261A (en) * 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
DK0470128T4 (da) * 1989-04-19 2003-12-01 Enzon Inc Aktive polyalkylenoxidcarbonater til modifikation af polypeptider
US5234903A (en) * 1989-11-22 1993-08-10 Enzon, Inc. Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute
CA2067224C (en) * 1989-12-01 2001-02-13 Manfred Kurfuerst Hirudin/polyalkylene glycol conjugates
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates

Also Published As

Publication number Publication date
JP2637010B2 (ja) 1997-08-06
ES2128329T3 (es) 1999-05-16
ATE176159T1 (de) 1999-02-15
HU211945A9 (en) 1996-01-29
CN1175465A (zh) 1998-03-11
CN1038035C (zh) 1998-04-15
NZ242084A (en) 1993-12-23
EE9400356A (et) 1996-04-15
ZA922110B (en) 1992-11-25
NO921142D0 (no) 1992-03-24
AU671045B2 (en) 1996-08-08
MX9201298A (es) 1992-10-01
EP0510356A1 (en) 1992-10-28
OA09760A (fr) 1993-11-30
CA2063886A1 (en) 1992-09-26
SI9210294A (en) 1995-10-31
IS3824A (is) 1992-09-26
NZ248022A (en) 1993-12-23
EP0510356B1 (en) 1999-01-27
US5539063A (en) 1996-07-23
DE69228269T2 (de) 1999-07-08
DK0510356T3 (da) 1999-09-13
NO921142L (no) 1992-09-28
AU657311B2 (en) 1995-03-09
US5792834A (en) 1998-08-11
US5849860A (en) 1998-12-15
GR3030049T3 (en) 1999-07-30
DE69228269D1 (de) 1999-03-11
RO109543B1 (ro) 1995-03-30
CA2063886C (en) 2002-08-20
FI107927B (fi) 2001-10-31
ZW4392A1 (en) 1992-09-23
BR9201015A (pt) 1992-11-24
JPH05117300A (ja) 1993-05-14
KR920018079A (ko) 1992-10-21
MY131095A (en) 2007-07-31
HU9200955D0 (en) 1992-05-28
AU1316092A (en) 1992-10-01
CN1108814C (zh) 2003-05-21
MW1892A1 (en) 1994-01-12
HUT60512A (en) 1992-09-28
US5834594A (en) 1998-11-10
FI20011554A7 (fi) 2001-07-17
BG60800B2 (bg) 1996-03-29
US5595732A (en) 1997-01-21
AU7761594A (en) 1995-01-12
FI921267A0 (fi) 1992-03-24
CS87192A3 (en) 1992-10-14
CY2169B1 (en) 2002-08-23
FI921267L (fi) 1992-09-26
US5747646A (en) 1998-05-05
CN1065465A (zh) 1992-10-21
FI20011554L (fi) 2001-07-17
US5559213A (en) 1996-09-24
IE920936A1 (en) 1992-10-07

Similar Documents

Publication Publication Date Title
IL101348A0 (en) Polyethylene glycol protein conjugates,their preparation and pharmaceutical compositions containing them
PL300194A1 (en) Interferon conjugate, method of obtaining same and pharmaceutical composition containing it
BR9913857A (pt) Formulações de proteìna
WO2001051510A3 (en) G-csf conjugates
FR2671800B1 (fr) Derive de la 5h-pyrrolo[3,4-b]pyrazine optiquement actif, sa preparation et les compositions pharmaceutiques qui le contiennent.
FR2762843B1 (fr) Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
ES2180629T3 (es) Usos terapeuticos de productos dimeros de proteina bactericida/aumentadora de la permeabilidad.
IL112665A (en) 5-Substituted derivatives of mycophenolic acid their preparation and pharmaceutical compositions containing them
IL112667A0 (en) 6-substituted derivatives of mycophenolic acid, their preparation and pharmaceutical compositions containing them
IL112664A0 (en) 4-amino derivatives of mycophenolic acid, their preparation and pharmaceutical compositions containing them
GR3007107T3 (cs)
UA100967C2 (ru) Конъюгаты нейбластина с полимерами и способы их применения
DE69327693D1 (de) Interferon-Alpha/Beta bindendes Protein, seine Herstellung und seine enthaltende pharmazeutische Zusammensetzungen
BR9106407A (pt) Formulacoes de concentrado fluivel,precipitado,seu preparo e usos agricolas
DE59107240D1 (de) Emulgatorfreie Emulsionspolymere in pharmazeutischen Zubereitungen mit verzögerter Wirkstofffreigabe und ihre Herstellung
YU29492A (sh) Konjugati proteina sa polietilenom
FR2679909B1 (fr) Polypeptides aptes a induire in vivo des anticorps inhibant l'invasion de globules rouges par des merozouites de p. falciparum, produits apparentes et leur application comme vaccin.
IT8748339A0 (it) Composizioni farmaceutiche ad atti vita'antineoplastica
RU93050376A (ru) Полиэтилен гликолевые соединения интерферона
UY23388A1 (es) Procedimiento para la preparacion de conjugados proteicos polietilenicos